aplastic anemia | Page 32 | Aplastic Anemia and MDS International Foundation

aplastic anemia

High-Dose Cyclophosphamide in Comparison with Antithymocyte Globulin for Treatment of Acquired Severe Aplastic Anemia

Author(s): 
Zhang F, Zhang L, Jing L, Zhou K, Wang H, Peng G, Li Y, Li Y, Li J, Ye L, Shi L, Fan H, Zhao X, Chu Y, Hao Y, Wang J
Primary Author: 
Zhang F
Journal Title: 
Exp Hematol
Original Publication Date: 
Jan 2013

A modified high-dose

Bone Marrow Diseases: 

Etiology and survival of aplastic anemia: a study based on clinical investigation

Author(s): 
Jain D, Kumar R, Tyagi N, Negi A, Pande A, Mahajan A, Pandey PK, Malik R, Raina V, Malik BK
Primary Author: 
Jain D
Journal Title: 
J Clin Lab Anal
Original Publication Date: 
Nov 2012

BACKGROUND:

Management of aplastic anemia is etiology driven, whether constitutional or acquired. Age, gender, and severity of disease also play crucial role in the survival of aplastic anemia. Since, inadequate data are available from India, the present study was conducted with the aim to evaluate the etiology and survival of aplastic anemia.
METHODS:

Three hundred patients were enrolled between May 2007 and April 2010. Severity analysis and chromosomal breakage study was performed and patients were followed up to calculate the survival rate.
RESULTS:

Bone Marrow Diseases: 

Caregivers

Over 65 million Americans take care of other adults, often parents or spouses, or children with special medical needs. Caregivers may be a day-to-day lifeline for patients, or they may support them from afar in otherways. These generous people need support to understand how they can best play their role.